COMPASS Pathways plc is a clinical-stage pharmaceutical company that develops psychedelic therapies for serious mental health challenges. The company's flagship candidate, COMP360, is a proprietary, high-purity synthetic psilocybin formulation designed to be administered in conjunction with psychological support. COMP360 is currently advancing through late-stage clinical trials, including Phase 3 studies for treatment-resistant depression, and Phase 2 trials for PTSD and anorexia nervosa. Operating primarily in the United Kingdom and the United States, COMPASS focuses entirely on research, clinical development, and regulatory pathways. The company does not currently have any approved products on the market and generates no commercial product revenue.
